Company / Net Income
Amphstar Pharmaceuticals, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$98.1M
FY2025
5-year range
$62.1M / $159.5M
FY2021-FY2025
Trend
-38.5%
vs FY2024
Sector context
#44 of 216
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s net income of $98M is higher than 80% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$6M in FY2018 to $160M in FY2024.
Based on SEC 10-K filings.
$98M in FY2025 with a 5-year CAGR of +133.8%. Top quartile in the Health Care sector.
Declined from $138M to $98M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +2.4%
- 5-Year CAGR
- +133.8%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 216This company $98.1M Sector average $454.3M
▼
-78.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +133.8%, indicating consistent growth.
- In FY2025, net income decreased 38.5% year-over-year.
- Ranks #44 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $98.1M | -38.5% |
| FY2024 | $159.5M | +16.0% |
| FY2023 | $137.5M | +50.5% |
| FY2022 | $91.4M | +47.1% |
| FY2021 | $62.1M | +4327.4% |
| FY2020 | $1.4M | -97.1% |
| FY2019 | $48.9M | +952.9% |
| FY2018 | -$5.7M | -257.3% |
| FY2017 | $3.6M | -62.9% |
| FY2016 | $9.8M | +452.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026